Physicians' Academy for Cardiovascular Education

GLP-1 receptor agonist is effective and safe in elderly type 2 diabetic patients

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1–5 trials

Literature - Warren M, Chaykin L, Trachtenbarg D, et al. - Diabetes Obes Metab 2018; published online ahead of print

Introduction and methods

Elderly patients with type 2 diabetes (T2DM) are at increased risk of hypoglycemia [1]. Semaglutide, a human GLP-1 analogue, reduces HbA1c and body weight (BW), either as monotherapy once weekly, or combined with other antidiabetic treatments, and is well tolerated in general [2-6].

In this pooled analysis of the SUSTAIN studies, the efficacy and safety of semaglutide was evaluated in elderly (≥65 years) vs non-elderly (<65 years) T2DM patients. In SUSTAIN 1-5, 3045 patients with T2DM were randomized to once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) or comparators (placebo, sitagliptin, exenatide or insulin).

Main results


Semaglutide consistently improved HbA1c and BW vs comparators, in elderly (≥65 years) and non-elderly patients with T2DM, and was well tolerated, suggesting that semaglutide may be an effective treatment option for elderly T2DM patients.


Show references

Find this article online at Diabetes Obes Metab

Share this page with your colleagues and friends: